NCT06340932View on ClinicalTrials.gov

Impact of Opioid Avoidance Protocol for ACL Reconstruction

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

April 27, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions
ACL TearPost Operative Pain
Interventions
DEVICE

Iovera

Cryoneurolysis of 5 sensory nerves (Intermediate branch of the AFCN, Medial Femoral Cutaneous Nerve, Suprapatellar branch of the saphenous nerve, 2 branches of the infrapatellar branch of the saphenous nerve) causing Wallerian degeneration

DRUG

Celecoxib

200mg BID

DRUG

Acetaminophen

1000mg q8h

DRUG

Oxycodone

As needed

DRUG

Tramadol

As needed

DRUG

Bupivacaine Hydrochloride

20mL of 0.25% bupivacaine HCl adductor canal block and 15mL of 0.25% bupivacaine HCl (+/- 5mL of normal saline) iPACK

DRUG

Acetaminophen 500Mg Cap

500mg q6h prn

Trial Locations (1)

15801

Penn Highlands Dubois, DuBois

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Matthew Varacallo

OTHER

NCT06340932 - Impact of Opioid Avoidance Protocol for ACL Reconstruction | Biotech Hunter | Biotech Hunter